Published in AIDS on August 01, 1996
Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol (1999) 18.82
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol (1997) 3.64
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (1998) 1.92
A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother (2000) 1.75
Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol (1997) 1.64
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother (2000) 1.59
Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. J Virol (1999) 1.50
Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol (1998) 1.38
Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob Agents Chemother (2002) 1.27
Protease inhibitors as antiviral agents. Clin Microbiol Rev (1998) 1.25
Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J Clin Microbiol (2001) 1.22
Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother (2000) 1.17
Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor. J Clin Microbiol (1999) 1.12
Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir. J Virol (2009) 0.99
In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob Agents Chemother (1997) 0.95
Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor. Antimicrob Agents Chemother (2001) 0.90
Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavir. Protein Sci (2008) 0.88
Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach. Biochem J (2009) 0.85
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. Antimicrob Agents Chemother (1997) 0.81
Adherence to HIV medications in a cohort of men who have sex with men: impact of September 11th. J Urban Health (2003) 0.80
A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV. Antimicrob Agents Chemother (2014) 0.80
Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing. PLoS One (2017) 0.75
Investigational protease inhibitors as antiretroviral therapies. Expert Opin Investig Drugs (2016) 0.75
Antiretroviral therapy for patients with HIV disease. Br J Clin Pharmacol (1998) 0.75
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods (1988) 7.74
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (1990) 5.70
(E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci U S A (1979) 5.28
A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues. J Med Chem (2001) 4.82
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med (1998) 4.77
Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis (1980) 4.67
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet (1998) 4.54
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. Development (1995) 4.38
CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci (2001) 4.12
Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med (1997) 3.62
Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol (1968) 3.29
Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-methylmercapto quinazolin-4(3H)-one. Pharm Acta Helv (1999) 3.24
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
A novel selective broad-spectrum anti-DNA virus agent. Nature (1986) 2.98
Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med (2001) 2.94
Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1988) 2.82
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother (1993) 2.52
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med (2000) 2.49
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
Angiogenesis: regulators and clinical applications. Biochem Pharmacol (2001) 2.47
An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. Proc Natl Acad Sci U S A (1991) 2.37
Letter: Keratoconjunctivitis caused by Adenovirus Type 19. Br Med J (1974) 2.36
Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet (2004) 2.33
Synthesis and antimicrobial activity of Schiff and Mannich bases of isatin and its derivatives with pyrimidine. Farmaco (1999) 2.31
Characterization of motifs which are critical for activity of the cyclic AMP-responsive transcription factor CREB. Mol Cell Biol (1991) 2.27
Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res (1987) 2.27
Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother (1987) 2.24
Differential distribution of hepatitis B surface antigen and hepatitis B core antigen in the liver of hepatitis B patients. Gastroenterology (1976) 2.17
Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis (1995) 2.16
Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother (1988) 2.16
Incomplete overlapping of biological, clinical, and environmental information in molecular epidemiological studies: a variety of causes and a cascade of consequences. J Epidemiol Community Health (2002) 2.13
Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus. J Virol Methods (1987) 2.10
Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A (1991) 2.08
[HIV infection declines among intravenous drug addicts in Barcelona: 1987-1993]. Med Clin (Barc) (1994) 2.04
Evaluation of six enzyme immunoassays for antibody against human immunodeficiency virus. Lancet (1986) 2.04
Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS (1999) 2.00
On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine. Proc Natl Acad Sci U S A (1981) 2.00
Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins. Mol Pharmacol (1981) 1.94
[Immunoglobulin A and human immunodeficiency virus type 1 infection in parenteral drug abuse addicts]. Med Clin (Barc) (1991) 1.93
HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology (1993) 1.92
The surgical management of nontraumatic ectopic lenses. J Pediatr Ophthalmol Strabismus (1996) 1.91
Synthesis and antiviral activity evaluation of some aminoadamantane derivatives. J Med Chem (1994) 1.91
Linear IgA disease of adults: association with lymphoproliferative malignancy and possible role of other triggering factors. Br J Dermatol (1990) 1.91
Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res (1997) 1.90
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS (2001) 1.90
Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol (1997) 1.89
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1996) 1.89
Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem (1989) 1.89
Insulin expression in pancreatic islet cells relies on cooperative interactions between the helix loop helix factor E47 and the homeobox factor STF-1. Mol Endocrinol (1994) 1.89
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr (1999) 1.88
Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate. Virology (1992) 1.87
Comprehensive management of children on a paediatric ward: a family approach. Arch Dis Child (1980) 1.86
The prevalence of antibody to hepatitis A antigen in various parts of the world: a pilot study. Am J Epidemiol (1977) 1.86
Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. J Med Chem (2000) 1.86
The IgM antibody response in rubella during pregnancy. J Med Microbiol (1971) 1.85
Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett (1979) 1.84
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A (2000) 1.83
Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs. Pharmacol Ther (1984) 1.82
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 1.81
CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages. J Virol (1998) 1.81
Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol (1998) 1.81
An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences. J Virol (1994) 1.81
Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother (1977) 1.79
Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes using a new method to uncover clock-like molecular evolution. FASEB J (2000) 1.78
Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo. J Virol (1968) 1.78
Synthesis of imidazo[1,2-a]pyridines as antiviral agents. J Med Chem (1998) 1.78
AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol (2001) 1.77
Cytotoxic activities of Mannich bases of chalcones and related compounds. J Med Chem (1998) 1.74
Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci U S A (1989) 1.74
Expression of human fibroblast interferon gene in Escherichia coli. Nature (1980) 1.72
Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A (1993) 1.71
Antiviral and antimetabolic activities of neplanocins. Antimicrob Agents Chemother (1985) 1.71
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS). J Med Chem (1986) 1.70
Mycobacteria, skins, and needles. Lancet (1969) 1.70
Enterovirus 70 haemorrhagic conjunctivitis in Zäire, 1981 versus 1972. Lancet (1981) 1.68
Comparative efficacy of antiherpes drugs in different cell lines. Antimicrob Agents Chemother (1982) 1.68
Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci U S A (1991) 1.67
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS (2000) 1.67
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun (1987) 1.67
The association of gonorrhoea and syphilis with premature birth and low birthweight. Genitourin Med (1993) 1.65
Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. Bioorg Med Chem Lett (2001) 1.64
Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob Agents Chemother (1991) 1.63